Deep Sequencing of the HIV-1 env Gene Reveals Discrete X4 Lineages and Linkage Disequilibrium between X4 and R5 Viruses in the V1/V2 and V3 Variable Regions

被引:28
|
作者
Zhou, Shuntai [1 ]
Bednar, Maria M. [1 ]
Sturdevant, Christa B. [2 ,5 ]
Hauser, Blake M. [1 ]
Swanstrom, Ronald [1 ,2 ,3 ,4 ]
机构
[1] Univ North Carolina Chapel Hill, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[2] Univ North Carolina Chapel Hill, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
[3] Univ North Carolina Chapel Hill, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA
[4] Univ North Carolina Chapel Hill, UNC Ctr AIDS Res, Chapel Hill, NC 27599 USA
[5] Elon Univ, Dept Biol, Elon, NC USA
基金
美国国家卫生研究院;
关键词
TREATMENT-NAIVE PATIENTS; CD4(+) T-CELLS; SUBTYPE C; CXCR4-USING HIV-1; LARGE POPULATION; TYPE-1; TROPISM; IMMUNODEFICIENCY; MARAVIROC; RECOMBINATION; TRIAL;
D O I
10.1128/JVI.00441-16
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
HIV-1 requires the CD4 receptor and a coreceptor (CCR5 [R5 phenotype] or CXCR4 [X4 phenotype]) to enter cells. Coreceptor tropism can be assessed by either phenotypic or genotypic analysis, the latter using bioinformatics algorithms to predict tropism based on the env V3 sequence. We used the Primer ID sequencing strategy with the MiSeq sequencing platform to reveal the structure of viral populations in the V1/V2 and C2/V3 regions of the HIV-1 env gene in 30 late-stage and 6 early-stage subjects. We also used endpoint dilution PCR followed by cloning of env genes to create pseudotyped virus to explore the link between genotypic predictions and phenotypic assessment of coreceptor usage. We found out that the most stringently sequence-based calls of X4 variants (Geno2Pheno false-positive rate [FPR] of <= 2%) formed distinct lineages within the viral population, and these were detected in 24 of 30 late-stage samples (80%), which was significantly higher than what has been seen previously by using other approaches. Non-X4 lineages were not skewed toward lower FPR scores in X4-containing populations. Phenotypic assays showed that variants with an intermediate FPR (2 to 20%) could be either X4/dual-tropic or R5 variants, although the X4 variants made up only about 25% of the lineages with an FPR of<10%, and these variants carried a distinctive sequence change. Phylogenetic analysis of both the V1/V2 and C2/V3 regions showed evidence of recombination within but very little recombination between the X4 and R5 lineages, suggesting that these populations are genetically isolated. IMPORTANCE Primer ID sequencing provides a novel approach to study genetic structures of viral populations. X4 variants may be more prevalent than previously reported when assessed by using next-generation sequencing (NGS) and with a greater depth of sampling than single-genome amplification (SGA). Phylogenetic analysis to identify lineages of sequences with intermediate FPR values may provide additional information for accurately predicting X4 variants by using V3 sequences. Limited recombination occurs between X4 and R5 lineages, suggesting that X4 and R5 variants are genetically isolated and may be replicating in different cell types or that X4/R5 recombinants have reduced fitness.
引用
收藏
页码:7142 / 7158
页数:17
相关论文
共 50 条
  • [1] In vitro inhibition of R5 HIV-1 infectivity by X4 V3-derived synthetic peptides
    Baritaki, S
    Dittmar, MT
    Spandidos, DA
    Krambovitis, E
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2005, 16 (02) : 333 - 336
  • [2] Presence of HIV-1 R5 Viruses in Cerebrospinal Fluid Even in Patients Harboring R5X4/X4 Viruses in Plasma
    Soulie, Cathia
    Tubiana, Roland
    Simon, Anne
    Lambert-Niclot, Sidonie
    Malet, Isabelle
    Canestri, Ana
    Brunet, Christel
    Murphy, Robert
    Katlama, Christine
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 (01) : 60 - 64
  • [3] Δ20 IFITM2 differentially restricts X4 and R5 HIV-1
    Wu, Wan-Lin
    Grotefend, Christopher Robert
    Tsai, Ming-Ting
    Wang, Yi-Ling
    Radic, Vladimir
    Eoh, Hyungjin
    Huang, I-Chueh
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (27) : 7112 - 7117
  • [4] Prediction of R5, X4, and R5X4 HIV-1 coreceptor usage with evolved neural networks
    Lamers, Susanna L.
    Salemi, Marco
    McGrath, Michael S.
    Fogel, Gary B.
    IEEE-ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS, 2008, 5 (02) : 291 - 300
  • [5] A systematic analysis of intrinsic regulators for HIV-1 R5 to X4 phenotypic switch
    Wei Yu
    Yu Wu
    Quantitative Biology, 2017, 5 (02) : 173 - 182
  • [6] Humanized mice dually challenged with R5 and X4 HIV-1 show preferential R5 viremia and restricted X4 infection of CCR5+CD4+ T cells
    Terahara, Kazutaka
    Ishige, Masayuki
    Ikeno, Shota
    Okada, Seiji
    Kobayashi-Ishihara, Mie
    Ato, Manabu
    Tsunetsugu-Yokota, Yasuko
    MICROBES AND INFECTION, 2015, 17 (05) : 378 - 386
  • [7] Differential HIV-1 X4 and R5 genetic signatures within the LTR, Tat and Vpr
    Aiamkitsumrit, Benjamas
    Nonnemacher, Michael
    Zhong, Wen
    Russo, Tatyana
    Pirrone, Vanessa
    Frantz, Brian
    Rimbey, Matthew
    Passic, Shendra
    Blakey, Brandon
    Parikh, Nirzari
    Martin-Garcia, Julio
    Jacobson, Jeffrey
    Moldover, Brian
    Dampier, William
    Wigdahl, Brian
    JOURNAL OF NEUROVIROLOGY, 2013, 19 : S2 - S3
  • [8] Cytopathicity of R5 and X4 HIV-1 isolates in human lymphoid tissue (ex vivo)
    Margolis, L
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (18) : 1614 - 1614
  • [9] Prediction of R5, X4 HIV-1 coreceptor usage based on physicochemical properties of envelope V3-loop using artificial neural network
    Falahi, S.
    Ravanshad, M.
    Kenarkoohi, A.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E241 - E241
  • [10] Determination of HIV-1 X4 and R5 genetic signatures within the LTR, Tat and Vpr
    Aiamkitsumrit, B.
    Nonnemacher, M. R.
    Zhong, W.
    Russo, T.
    Pirrone, V
    Frantz, B.
    Rimby, M.
    Passic, S.
    Blakey, B.
    Parikh, N.
    Martin-Garcia, J.
    Jacobson, J. M.
    Moldover, B.
    Dampier, W.
    Wigdahl, B.
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2014, 9 (01) : 4 - 4